[Featured Stock] 'Lock-up Release' Samsung Biologics Falls 1.5% Intraday

Samsung Biologics is experiencing a decline of around 1.5% during trading hours.

At 9:12 AM on the 2nd, Samsung Biologics was trading at 769,000 KRW, down 1.54% from the previous trading day. The company's stock price dropped to 756,000 KRW immediately after the market opened, falling nearly 3%, but it is estimated that the decline narrowed shortly thereafter.

The main reason behind the weak stock price is the expiration of the lock-up period for employee stock ownership. In April of last year, the company conducted a paid-in capital increase targeting the employee stock ownership association and existing shareholders. As of the 28th of last month, the one-year lock-up period for a total of 625,450 shares allocated to the employee stock ownership association was lifted, allowing sales from that day onward. This volume accounts for 12.5% of the total public offering shares.

The issuance price for the paid-in capital increase was 639,000 KRW. Considering the current stock price level, it appears that nearly 20% profit has been realized.

This content was produced with the assistance of AI translation services.